230 related articles for article (PubMed ID: 30024813)
21. Rationally Repurposing Ruxolitinib (Jakafi (®)) as a Solid Tumor Therapeutic.
Tavallai M; Booth L; Roberts JL; Poklepovic A; Dent P
Front Oncol; 2016; 6():142. PubMed ID: 27379204
[TBL] [Abstract][Full Text] [Related]
22. Synergism between ATM and PARP1 Inhibition Involves DNA Damage and Abrogating the G
Mak JPY; Ma HT; Poon RYC
Mol Cancer Ther; 2020 Jan; 19(1):123-134. PubMed ID: 31597711
[TBL] [Abstract][Full Text] [Related]
23. Targeting PARP and autophagy evoked synergistic lethality in hepatocellular carcinoma.
Zai W; Chen W; Han Y; Wu Z; Fan J; Zhang X; Luan J; Tang S; Jin X; Fu X; Gao H; Ju D; Liu H
Carcinogenesis; 2020 May; 41(3):345-357. PubMed ID: 31175354
[TBL] [Abstract][Full Text] [Related]
24. Pazopanib and HDAC inhibitors interact to kill sarcoma cells.
Tavallai S; Hamed HA; Grant S; Poklepovic A; Dent P
Cancer Biol Ther; 2014 May; 15(5):578-85. PubMed ID: 24556916
[TBL] [Abstract][Full Text] [Related]
25. Enhancing CHK1 inhibitor lethality in glioblastoma.
Tang Y; Dai Y; Grant S; Dent P
Cancer Biol Ther; 2012 Apr; 13(6):379-88. PubMed ID: 22313687
[TBL] [Abstract][Full Text] [Related]
26. GZ17-6.02 and Doxorubicin Interact to Kill Sarcoma Cells via Autophagy and Death Receptor Signaling.
Booth L; West C; Hoff DV; Dent P
Front Oncol; 2020; 10():1331. PubMed ID: 32983965
[TBL] [Abstract][Full Text] [Related]
27. PARP1 blockade is synthetically lethal in XRCC1 deficient sporadic epithelial ovarian cancers.
Ali R; Alabdullah M; Alblihy A; Miligy I; Mesquita KA; Chan SY; Moseley P; Rakha EA; Madhusudan S
Cancer Lett; 2020 Jan; 469():124-133. PubMed ID: 31669203
[TBL] [Abstract][Full Text] [Related]
28. GZ17-6.02 interacts with proteasome inhibitors to kill multiple myeloma cells.
Booth L; Roberts JL; West C; Dent P
Oncotarget; 2024 Mar; 15():159-174. PubMed ID: 38441437
[TBL] [Abstract][Full Text] [Related]
29. PARP1 expression drives the synergistic antitumor activity of trabectedin and PARP1 inhibitors in sarcoma preclinical models.
Pignochino Y; Capozzi F; D'Ambrosio L; Dell'Aglio C; Basiricò M; Canta M; Lorenzato A; Vignolo Lutati F; Aliberti S; Palesandro E; Boccone P; Galizia D; Miano S; Chiabotto G; Napione L; Gammaitoni L; Sangiolo D; Benassi MS; Pasini B; Chiorino G; Aglietta M; Grignani G
Mol Cancer; 2017 Apr; 16(1):86. PubMed ID: 28454547
[TBL] [Abstract][Full Text] [Related]
30. Poly(ADP-ribose) Polymerase (PARP) and PARP Inhibitors: Mechanisms of Action and Role in Cardiovascular Disorders.
Henning RJ; Bourgeois M; Harbison RD
Cardiovasc Toxicol; 2018 Dec; 18(6):493-506. PubMed ID: 29968072
[TBL] [Abstract][Full Text] [Related]
31. GZ17-6.02 kills prostate cancer cells
Booth L; Roberts JL; West C; Dent P
Front Oncol; 2022; 12():1045459. PubMed ID: 36408163
[TBL] [Abstract][Full Text] [Related]
32. GZ17-6.02 and palbociclib interact to kill ER+ breast cancer cells.
Booth L; West C; Moore RP; Von Hoff D; Dent P
Oncotarget; 2022; 13():92-104. PubMed ID: 35035775
[TBL] [Abstract][Full Text] [Related]
33. Development and validation of a LC-MS/MS method for the quantification of the checkpoint kinase 1 inhibitor SRA737 in human plasma.
Zangarini M; Berry P; Sludden J; Raynaud FI; Banerji U; Jones P; Edwards D; Veal GJ
Bioanalysis; 2017 Jul; 9(13):1001-1010. PubMed ID: 28692309
[TBL] [Abstract][Full Text] [Related]
34. GZ17-6.02 initiates DNA damage causing autophagosome-dependent HDAC degradation resulting in enhanced anti-PD1 checkpoint inhibitory antibody efficacy.
Booth L; Roberts JL; West C; Von Hoff D; Dent P
J Cell Physiol; 2020 Nov; 235(11):8098-8113. PubMed ID: 31951027
[TBL] [Abstract][Full Text] [Related]
35. HDAC inhibitors enhance the lethality of low dose salinomycin in parental and stem-like GBM cells.
Booth L; Roberts JL; Conley A; Cruickshanks N; Ridder T; Grant S; Poklepovic A; Dent P
Cancer Biol Ther; 2014 Mar; 15(3):305-16. PubMed ID: 24351423
[TBL] [Abstract][Full Text] [Related]
36. Mechanistic Dissection of PARP1 Trapping and the Impact on In Vivo Tolerability and Efficacy of PARP Inhibitors.
Hopkins TA; Shi Y; Rodriguez LE; Solomon LR; Donawho CK; DiGiammarino EL; Panchal SC; Wilsbacher JL; Gao W; Olson AM; Stolarik DF; Osterling DJ; Johnson EF; Maag D
Mol Cancer Res; 2015 Nov; 13(11):1465-77. PubMed ID: 26217019
[TBL] [Abstract][Full Text] [Related]
37. The Lethality of [Pazopanib + HDAC Inhibitors] Is Enhanced by Neratinib.
Booth L; Roberts JL; Poklepovic A; Dent P
Front Oncol; 2019; 9():650. PubMed ID: 31380285
[TBL] [Abstract][Full Text] [Related]
38. PDE5 inhibitors enhance celecoxib killing in multiple tumor types.
Booth L; Roberts JL; Cruickshanks N; Tavallai S; Webb T; Samuel P; Conley A; Binion B; Young HF; Poklepovic A; Spiegel S; Dent P
J Cell Physiol; 2015 May; 230(5):1115-27. PubMed ID: 25303541
[TBL] [Abstract][Full Text] [Related]
39. Palbociclib augments Neratinib killing of tumor cells that is further enhanced by HDAC inhibition.
Booth L; Roberts JL; Rais R; Cutler RE; Diala I; Lalani AS; Poklepovic A; Dent P
Cancer Biol Ther; 2019; 20(2):157-168. PubMed ID: 30183517
[TBL] [Abstract][Full Text] [Related]
40. Poly(ADP-ribose)polymerase (PARP) inhibition and anticancer activity of simmiparib, a new inhibitor undergoing clinical trials.
Yuan B; Ye N; Song SS; Wang YT; Song Z; Chen HD; Chen CH; Huan XJ; Wang YQ; Su Y; Shen YY; Sun YM; Yang XY; Chen Y; Guo SY; Gan Y; Gao ZW; Chen XY; Ding J; He JX; Zhang A; Miao ZH
Cancer Lett; 2017 Feb; 386():47-56. PubMed ID: 27847302
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
